The Landscape of Immune Cells Infiltrating in Prostate Cancer
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was to explore the infiltration pattern of immune cells in the prostate cancer (PCa) microenvironment and evaluate the possibility of specific infiltrating immune cells as potential prognostic biomarkers in PCa. METHODS: -value < 0.05 were subsequently merged and divided into normal or tumor groups. The differences of 22 immune cells between normal and tumor tissues were analyzed along with potential infiltrating correlations among 22 immune cells and Gleason grades. SNV data from TCGA was used to calculate the TMB score. A univariate and multivariate regression were used to evaluate the prognostic effects of immune cells in PCa. RESULTS: Ten immune cells with significant differences were identified, including seven increased and three decreased infiltrating immune cells from 190 normal prostate tissues and 537 PCa tissues. Among them, the percentage of infiltration of resting NK cells increased the most, whereas the percentage of infiltration of resting mast cells decreased the most. In normal tissues, CD8+ T cells had the strongest infiltrating correlation with monocytes, while activated NK cells and naive B cells were the highest in PCa tissues. Moreover, the infiltration of five immune cells was significantly associated with TMB score and mutations of immune gene change the infiltration of immune cells. The Area Under Curve (AUC) of the multivariate regression model for the five- and 10-year survival prediction of PCa reached 0.796 and 0.862. The validation cohort proved that the model was reproducible. CONCLUSIONS: This study demonstrated that different infiltrating immune cells in prostate cancer, especially higher infiltrating M1 macrophages and neutrophils in PCa tissue, are associated with patients' prognosis, suggesting that these two immune cells might be potential targets for PCa diagnosis and prognosis of treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Cancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Correlation Coefficients: Appropriate Use and Interpretation
Schober, P., Boer, C., & Schwarte, L. A. (2018) · Anesthesia & Analgesia · doi:10.1213/ane.0000000000002864 · Cited by 10,986 · cited 1×
“89 represents a strong correlation (40).”
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517
Yu, Y. P., Landsittel, D., Jing, L., Nelson, J., Ren, B., Liu, L., McDonald, C., Thomas, R., Dhir, R., Finkelstein, S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.158 · Cited by 758
Labbé, D. P., Zadra, G., Yang, M., Reyes, J. M., Lin, C. Y., Cacciatore, S., Ebot, E. M., Creech, A. L., Giunchi, F., Fiorentino, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12298-z · Cited by 174 · cited 3×
“Tumor TCGA, GSE41969 (21), GSE44353 (27), GSE6606 (28), GSE6287 (22), GSE64333 (29),GSE7055 (30),GSE68555 (31),GSE68882 (32), GSE70768 (23),”
Cortesi, F., Delfanti, G., Grilli, A., Calcinotto, A., Gorini, F., Pucci, F., Lucianò, R., Grioni, M., Recchia, A., Benigni, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.058 · Cited by 100 · cited 1×
“Invariant Natural Killer T (iNKT) cells were found to delay PCa progression by sculpting the TME (7).”
BackgroundXie, H., Li, C., Dang, Q., Chang, L. S., & Li, L. (2016) · Oncotarget · doi:10.18632/oncotarget.6372 · Cited by 49 · cited 1×
“In the procession of PCa metastasis patients, mast cells could enhance PCa resistance to chemotherapy and radiotherapy, and eventually progress to metastasis stage (8).”
Background
Cited by
The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives
Majidpoor, J., & Mortezaee, K. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108707 · Cited by 236
O’Dea, X., Tsz Kit Ng, D., O’Dea, M., & Shkuratskyy, V. (2026) · Policy Futures in Education · doi:10.1177/14782103241287401 · Cited by 69
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Metadata
- Authors
- Wu, Z., Chen, H., Luo, W., Zhang, H., Li, G., Zeng, F., & Deng, F.
- Venue
- Frontiers in Oncology
- Publisher
- Frontiers Media SA
- Published
- 2020-10-29
- Volume
- 10
- Pages
- 517637-517637
- ISSN
- 2234-943X (ISSN-L)
- OpenAlex
- W3096656318
- Cited by
- 104
- References
- 9
- FWCI
- 6.26
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.